The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years

Introduction Darunavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor boosted with ritonavir (DRV/r) or cobicistat. Objective This study provided continued access to DRV/r and assessed long-term safety in patients aged 3 to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug safety 2021-04, Vol.44 (4), p.439-446
Hauptverfasser:	Violari, Avy, Masenya, Maysseb, Blanche, Stephane, Vanveggel, Simon, Hufkens, Veerle, Chetty, Polan, Opsomer, Magda
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adults Adverse events Antiretroviral drugs Antiviral drugs Asthma Birth control Child Child, Preschool Consent Darunavir - adverse effects Dosage Drug dosages Drug Safety and Pharmacovigilance Drug withdrawal Follow-Up Studies Health Services Accessibility HIV HIV Infections - drug therapy HIV Protease Inhibitors - adverse effects HIV-1 Human immunodeficiency virus Humans Life Sciences & Biomedicine Lipoatrophy Medicine Medicine & Public Health Original Research Article Patients Pediatrics Pharmacology & Pharmacy Pharmacology/Toxicology Pneumonia Protease inhibitors Proteinase inhibitors Public, Environmental & Occupational Health Ritonavir Ritonavir - adverse effects Safety Science & Technology Teenagers Toxicology Tuberculosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Darunavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor boosted with ritonavir (DRV/r) or cobicistat. Objective This study provided continued access to DRV/r and assessed long-term safety in patients aged 3 to
ISSN:	0114-5916 1179-1942
DOI:	10.1007/s40264-020-01032-0